Study of the effects of ocular hypotensive drugs on number of neurons in the retinal ganglion layer in a rat experimental glaucoma

European Journal of Ophthalmology

Volumn 19, Issue 6, 2009, Pages 963-970

  Villena, Alicia ^a   Díaz, Florentina ^a   Vidal, Lourdes ^a   Moreno, Mercedes ^a   García Campos, Jose ^a   De Vargas, Ignacio Pérez ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Brimonidine; Experimental glaucoma; Latanoprost; Number of neurons; Retinal ganglion layer; Timolol

Indexed keywords

BRIMONIDINE; LATANOPROST; TIMOFTOL; TIMOLOL; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; PROSTAGLANDIN F; QUINOXALINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CAUTERIZATION; CELL COUNT; CELL LOSS; CONTROLLED STUDY; GLAUCOMA; INTRAOCULAR HYPERTENSION; MALE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; TONOMETER; WISTAR RAT; ANIMAL; CELL PROTECTION; CELL SURVIVAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; INTRAOCULAR PRESSURE; OCULOPLETHYSMOGRAPHY; PATHOLOGY; RETINA GANGLION CELL; RETINA NERVE CELL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL COUNT; CELL SURVIVAL; CYTOPROTECTION; DISEASE MODELS, ANIMAL; GLAUCOMA; INTRAOCULAR PRESSURE; MALE; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; RATS; RATS, WISTAR; RETINAL GANGLION CELLS; RETINAL NEURONS; TIMOLOL; TONOMETRY, OCULAR;

EID: 73949123493     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900611     Document Type: Article

References (43)

1. Hoyng PF, van Beek LM. Pharmacological therapy for glaucoma: a review. Drugs 2000; 59: 411-34.
2. Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocular Pharmacol 1993; 9: 373-84.
3. Frishman WH, Fuksbrumer MS, Tannenbaum M. Topical ophthalmic ß-adrenergic blockade for the treatment of glaucoma and ocular hypertension. J Clin Pharmacol 1994; 34: 795-803.
4. Orzalesi N, Rossetti L, Bottoli A, Fogagnolo P. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Ophthalmology 2006; 113: 239-46.
5. Tamada Y, Taniguchi T, Murase H, Yamamoto T, Kitazawa Y. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther 2001; 17: 19-25.
6. Husain S, Whitlock NA, Rice DS, Crosson CE. Effects of latanoprost on rodent intraocular pressure. Exp Eye Res 2006; 83: 1453-8.
7. Crowston JG, Aihara M, Lindsey JD, Weinreb RN. Effect of latanoprost on outflow facility in the mouse. Invest Ophthalmol Vis Sci 2004; 45: 2240-5.
8. Weinreb RN, Toris CB, Gabelt BT, Lindsey JD, Kaufman PL. Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002; 47: S53-S64.
9. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996; 41 (suppl 1): S9-S18.
10. Ahmed AKMF, Hegazy K, Chaudhary P, Sharma SC. Neuroprotective effect of á2 agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res 2001; 913: 133-9.
11. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one month dose response study. Ophthalmology 1997; 104: 131-6.
12. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol 1999; 128: 8-14.
13. García-Valenzuela E, Shareef S, Walsh J, Sharma SC. Programmed cell death of retinal ganglion cells during experimental glaucoma. Exp Eye Res 1995; 61: 33-44.
14. Morrison JC, Moore CG, Deppmeier LM, Gold BG, Meshul CK, Johnson EC. A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res 1997; 64: 85-96
15. Laquis S, Chaudhary P, Sharma SC. The patterns of retinal ganglion cell death in hypertensive eyes. Brain Res 1998; 784: 100-4.
16. Ueda J, Sawaguchi S, Hanyu T, et al. Experimental glaucoma model in the rat induced by laser trabecular photocoagulation after an intracameral injection of India ink. Jpn J Ophthalmol 1998; 42: 337-44.
17. Mittag TW, Danias J, Pohorenec G, et al. Retinal damage after 3 to 4 months of elevated intraocular pressure in a rat glaucoma model. Invest Ophthalmol Vis Sci 2000; 41: 3451-9.
18. Wang X, Tay SS, Ng YK. An immunohistochemical study of neuronal and glial cell reactions in retinae of rats with experimental glaucoma. Exp Brain Res 2000; 132: 476-84.
19. Yu S, Tanabe T, Yoshimura N. A rat model of glaucoma induced by episcleral vein ligation. Exp Eye Res 2006; 83: 758-70.
20. Hernández M, Urcola JH, Vecino E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp Eye Res 2008; 86: 798-806.
21. Danias J, Shen F, Kavalarakis M, et al. Characterization of retinal damage in the episcleral vein cauterization rat glaucoma model. Exp Eye Res 2006; 82: 219-28.
22. Shareef SR, García-Valenzuela E, Salierno A, Walsh J, Sharma SC. Chronic ocular hypertension following episcleral venous occlusion in rats. Exp Eye Res 1995; 61: 379-82.
23. Pang IH, Wang WH, Clark AF. Acute effects of glaucoma medications on rat intraocular pressure. Exp Eye Res 2006; 80: 207-14.
24. Levkovitch-Verbin H, Quigley HA, Martin KR, Valenta D, Baumrind LA, Pease ME. Translimbal laser photocoagulation to the trabecular meshwork as a model of glaucoma in rats. Invest Ophthalmol Vis Sci 2002; 43: 402-10.
25. Wolf HK, Buslei R, Schmidt-Kastner R, et al. NeuN: a useful neuronal marker for diagnostic histopathology. J Histochem Cytochem 1996; 44: 1167-71.
26. Canola K, Angénieux B, Tekaya M, et al. Retinal stem cells transplanted into models of late stages of retinitis pigmentosa preferentially adopt a glial or a retinal ganglion cell fate. Invest Ophthalmol Vis Sci 2007; 48: 446-54.
27. Dijk F, Bergen AA, Kamphuis W. GAP-43 expression is upregulated in retinal ganglion cells after ischemia/reperfusion-induced damage. Exp Eye Res 2007; 84: 858-67.
28. Zhong L, Bradley J, Schubert W, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Invest Ophthalmol Vis Sci 2007; 48: 1212-8.
29. Raymond ID, Vila A, Huynh UN, Brecha NC. Cyan fluorescent protein expression in ganglion and amacrine cells in a thy1-CFP transgenic mouse retina. Mol Vision 2008; 14: 1559-74.
30. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42: 2849-55.
31. Agar A, Yip SS, Hill MA, Coroneo MT. Pressure related apoptosis in neuronal cell lines. J Neurosci Res 2000; 60: 495-503.
32. Wang X, Ng YK, Tay SS. Factors contributing to neuronal degeneration in retinas of experimental glaucomatous rats. J Neurosci Res 2005; 82: 674-89.
33. Lau J, Dang M, Hockmann K, Ball AK. Effect of acute delivery of endothelin-1 on retinal ganglion cell loss in the rat. Exp Eye Res 2006; 82: 132-45.
34. Morrison JC, Johnson EC, Funk RHW. Microvasculature of the rat optic nerve head. Invest Ophthalmol Vis Sci 1999; 40: 1702-9.
35. Neufeld AH. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res Bull 2004; 62: 455-9.
36. Goto W, Ota T, Morikawa N, et al. Protective effect of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res 2002; 958: 10-9.
37. Vidal L, Díaz F, Villena A, Moreno M, García-Campos J, Pérez de Vargas I. Nitric oxide synthase in retina and optic nerve head of rat with increased intraocular pressure and effect of timolol. Brain Res Bull 2006; 70: 406-13
38. Drago F, Valzelli S, Emmi I, Marino A, Scalia CC, Marino V. Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp Eye Res 2001; 72: 479-86.
39. Kashiwagi K, Kanai N, Tsuchida T, et al. Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2) induction, affinity to prostaglandin transporter, and intraocular metabolism. Exp Eye Res 2002; 74: 41-9.
40. McCullough L, Wu L, Haughey N, et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004; 24: 257-68.
41. Wen R, Chang T, Li Y, Cao W, Steinberg R. 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996; 16: 5986-92.
42. Osborne NN. Inhibition of cAMP production by alpha 2-adrenoceptor stimulation in rabbit retina. Brain Res 1991; 553: 84-8.
43. Dreyer E, Grosskreutz C. Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG). Clin Neurosci 1997; 4: 270-3.